Vascular and Interventional Radiology is unique among the subspecialties of Radiology in a sense that it does not end at imaging or diagnosis, it carries a dimension of therapy. From this perspective, our research is focused on exploring innovative concepts, approaches, technologies, methods, techniques, and drugs, with an aim to develop safe and effective treatments for diseases and to provide sound solution for clinical problems, using non-surgical interventions, in a minimally-invasive way. Our research interest has been focused on the treatment of hepatocellular carcinoma, the treatment cerebrovascular diseases, the treatment of aortic diseases, gynecological diseases and urological diseases, as well as the development of navigational systems for interventional procedures, and the application of artificial intelligence in the assessment of clinical outcome of vascular diseases.
- Early Stent-Assisted Angioplasty in Symptomatic Intracranial Stenosis (ESASIS): A randomized control trial of stent-assisted angioplasty versus medical therapy.
- Lipiodol-based Transcatheter Arterial Chemoembolization for unresectable hepatocellular carcinoma: A randomized controlled trial of aqueous cisplatin emulsion versus cisplatin particle suspension
- Ablative chemoembolization for unresectable and large hepatocellular carcinoma
- A study on the angioarchitecture of hepatocellular carcinoma
- Microwave ablation for uterine fibroids
Ablative chemoembolization for hepatocellular carcinoma: a prospective phase I case-control comparison with conventional chemoembolization
This paper is about a brand-new loco-regional treatment concept which has been shown to be potentially promising in this phase I study and published in the top journal of the specialty. There has been no major breakthrough in the outcome of loco-regional treatment for HCC since the invention of TACE 30 years ago, this new treatment may bring about such a breakthrough.
PURPOSE: To evaluate the feasibility, safety and treatment effectiveness of ablative chemoembolization (ACE) in the treatment of hepatocellular carcinoma (HCC) and compare to a similar patient cohort that underwent conventional chemoembolization (cTACE).
MATERIALS AND METHODS: This was a prospective phase I non-randomized study conducted between March 2013 and October 2016 in accordance to the Declaration of Helsinki and Declaration Good Clinical Practice with written informed consent. There were 36 males and 8 females, of median age (interquartile range) 64 (58,74) years and 74.5 (70 ,80) years respectively. The primary endpoints were treatment safety and tumor response. The secondary endpoints were time to progression (TTP), progression free survival (PFS), conversion to partial hepatectomy, and viable HCC within the tumor specimen. The study endpoints of the study group (n=22) were compared to those of a case-matched control group (n=22) of patients who received conventional cTACE during the same period using a Pearson Chi-square test.
RESULTS: ACE was successfully completed in all cases without complication. The complete response rates by patient or by tumor were both 100%. The median TTP and median PFS were significantly longer in the study group (both were 28 months versus 10 months, P<0.001). The number of patient conversions to hepatectomy was 7 for ACE and 3 for cTACE. Viable tumor was found in 2/8 (ACE) and 3/3 (cTACE) of tumor specimens.
CONCLUSIONS: ACE is a feasible, safe, and well-tolerated treatment for patients with HCC, which is highly effective and may be more effective than cTACE in achieving complete response.
REFERENCE: Yu SCH, Chan SL, Lee KF, Hui JWY, Hui EP, Chu CM, Chan AW, Cheung S, Li L, Wong J, Yeo WMM. Ablative chemoembolization for hepatocellular carcinoma: a prospective phase I case-control comparison with conventional chemoembolization.
Radiology 2018 April; 287(1): 340-348, doi: 10.1148/radiol.2017170154
Hepatocellular carcinoma on DSA
Hepatocellular carcinoma after treated with Ablative Chemoembolization
Absence of tumor vascularity following treatment with Ablative Chemoembolization
Surgical specimen of hepatocellular carcinoma obtained after treatment with Ablative Chemoembolization
Oxytocin-augmented and non-sedating High-Intensity-Focused-Ultrasound (HIFU) for uterine fibroids showed promising outcome as compared to HIFU alone or uterine artery embolization
A high-intensity-focused-ultrasound (HIFU) treatment for uterine fibroids using a modified energy transmission protocol and oxytocin augmentation is being proposed, to aim for an effective and well-tolerable treatment to be given as an out-patient procedure without anesthesia or sedation. The objective of this study was to evaluate the safety and treatment effectiveness of this new protocol. The treatment outcomes of 9 consecutive patients (study group) were compared to those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n=24) or uterine artery embolization (UAE) (n=27). There was no major adverse event. At 3 months, the median proportion of fibroid volume as compared to baseline was 51.1% in the study group, significantly smaller than that in the control groups (HIFU 76.6%, UAE 66.2%). At 6 months, all patients in the study group became symptom free (9/9, 100%), a result significantly better than that of both control groups; the proportion of patients with good quality of life was significantly higher in the study group (5/7, 71.4%) as compared to the control groups (HIFU 3/24, 12.5%; UAE 7/27, 25.9%). Within 24 months, no one in the study HIFU group required re-intervention, a result significantly better than that in the control HIFU group (15/24, 62.5%). The treatment could result in very promising long-term imaging and clinical outcome that may be better than those of uterine artery embolization, a randomized control trial of larger scale is required for further evaluation of this treatment.
Ultrasound image of a 40 years old lady showed a submucosal fibroid of 60.9mm long.
The submucosal fibroid shrank to 13mm in length 12 months after oxytocin-augmented HIFU
Thickness-to-Height Ratio of Intravesical Prostatic Protrusion Predicts the Clinical Outcome and Morbidity of Prostate Artery Embolization for Benign Prostatic Hypertrophy
PURPOSE: To evaluate the presence of intravesical prostatic protrusion (IPP) and its thickness-to-height ratio (T/H ratio) as a predictor for the clinical outcome and morbidity of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH).
MATERIALS AND METHODS: This was a prospective, single-center, institutional review board approved study from June 2015 to December 2018, of 82 consecutive patients (aged 53 to 79, median 66 years) with International Prostate Symptom Score (IPSS) ≥15, and Quality of Life score (QOL) ≥3. The presence of IPP and its T/H ratio were assessed on baseline MRI for their correlation with the clinical outcomes of suboptimal IPSS (IPSS ≥10) and suboptimal QOL (QOL ≥3) up to 12 months post-PAE, and the occurrence of post-procedure complications (≤30 days) which caused a certain degree of urinary outflow obstruction.
RESULTS: IPP was present in 57 of 82 patients (69.5%). The presence of IPP correlated with the occurrence of post-procedure complications (P = 0.009), but not with suboptimal IPSS at 12 months (P=0.758). IPP with T/H ratio ≤1.3 correlated with suboptimal IPSS at 12 months (P=0.025), suboptimal QOL at 6 months (P=0.025) and 12 months (P=0.008), as well as with the occurrence of post-procedure complication (P = 0.009). Chi-square test was used for analysis.
CONCLUSIONS: IPP with a T/H ratio ≤ 1.3 predicted the occurrence of post-procedure complications with urinary obstruction. T/H ratio ≤ 1.3 but not the presence of IPP alone predicted the clinical outcome up to 12 months after PAE.
Prostate gland vascularity just before embolization
Absence of prostate vascularity after embolization
Intravesical prostatic protrusion following embolization as shown in coronal plane
Intravesical prostatic protrusion following embolization as shown in axial plane
Intravenous C-Arm Conebeam CT angiography following long-term flow-diverter implantation: technologic evaluation and preliminary results.
BACKGROUND AND PURPOSE: A non-invasive investigation with high spatial resolution and without metal artifacts is necessary for long term imaging follow-up following flow-diverter implantation. We aimed to evaluate the diagnostic value of cone-beam CT angiography with intravenous contrast enhancement (IVCBCTA) in the assessment of vascular status following implantation of Pipeline embolization device (PED), and to analyze the preliminary results of vascular status following long-term PED implantation.
MATERIALS AND METHODS: This was an on-going prospective study approved by Institutional-Review-Board. Consecutive and consented patients with intracranial aneurysms treated with PED were included. Patients with modified Rankin scale score 4 to 5 were excluded. Median and interquartile range of PED to IVCBCTA time interval was 56.6 months and 42.9 to 62.4 months respectively. IVCBCTA was performed with the patient fully conscious, using C-arm CT with flat-panel detector.
RESULTS: There were 31 patients and 34 vascular segments. In all 34 cases, contrast effect and image quality was good and indistinguishable from that of intraarterial CBCTA. Metal artifact occurred in all 14 cases with coil mass, PED was obscured in 3 cases. In all 31 cases, there was no residual aneurysm, no vascular occlusion, one vascular stenosis (50%), good PED apposition to vessel, and no PED-induced calcification. All 28 PED-covered side branches were patent and not narrowed.
CONCLUSIONS: IVCBCTA is potentially promising and useful for effective evaluation of the vascular status following intracranial flow-diverters, PED for intracranial aneurysms is probably safe and promising for long-term placement, with favorable morphological outcome and without delayed complications.